Latest news with #Suvannavejh
Business Insider
26-06-2025
- Business
- Business Insider
Mizuho Securities Sticks to Their Buy Rating for Adverum Biotechnologies (ADVM)
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Adverum Biotechnologies (ADVM – Research Report) today and set a price target of $12.00. The company's shares closed today at $2.58. Confident Investing Starts Here: Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Insmed, and Verastem. According to TipRanks, Suvannavejh has an average return of -7.4% and a 40.59% success rate on recommended stocks. Adverum Biotechnologies has an analyst consensus of Strong Buy, with a price target consensus of $17.00. The company has a one-year high of $10.14 and a one-year low of $1.78. Currently, Adverum Biotechnologies has an average volume of 345.4K. Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is neutral on the stock. Last month, Laurent Fischer, the CEO, PRESIDENT AND DIRECTOR of ADVM sold 9,126.00 shares for a total of $18,252.00.
Business Insider
25-06-2025
- Business
- Business Insider
Mizuho Securities Remains a Buy on Corvus Pharmaceuticals (CRVS)
Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Corvus Pharmaceuticals (CRVS – Research Report) today and set a price target of $11.00. The company's shares closed today at $4.34. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Suvannavejh is an analyst with an average return of -8.4% and a 40.35% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Harmony Biosciences Holdings, and Insmed. Corvus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $13.00.
Yahoo
18-06-2025
- Business
- Yahoo
Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110
Insmed Inc. (NASDAQ:INSM) is one of the 10 best growth stocks to buy according to billionaires. On June 10, Mizuho analyst Graig Suvannavejh reaffirmed his Outperform rating on Insmed and raised the price target from $96 to $110. The revision follows the encouraging Phase 2b results for Treprostinil Palmitil Inhalation Powder (TPIP) in treating pulmonary arterial hypertension. Suvannavejh describes the data as highly positive, suggesting TPIP could become a leading treatment option in the respective area. A scientist using sophisticated laboratory equipment to analyze a sample of a therapeutic candidate. The analyst believes the trial's success strengthens Insmed's growth outlook and opens the door for further upside to current earnings estimates. The tone of the note reflects the analyst's strong confidence in TPIP's potential and its impact on Insmed's long-term value. Insmed Inc. (NASDAQ:INSM) is a global biopharmaceutical company that develops therapies for serious diseases. It has a commercial product, ARIKAYCE, and a pipeline that includes clinical-stage programs, brensocatib, TPIP, and INS1201, as well as pre-clinical research programs. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
18-06-2025
- Business
- Yahoo
Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110
Insmed Inc. (NASDAQ:INSM) is one of the 10 best growth stocks to buy according to billionaires. On June 10, Mizuho analyst Graig Suvannavejh reaffirmed his Outperform rating on Insmed and raised the price target from $96 to $110. The revision follows the encouraging Phase 2b results for Treprostinil Palmitil Inhalation Powder (TPIP) in treating pulmonary arterial hypertension. Suvannavejh describes the data as highly positive, suggesting TPIP could become a leading treatment option in the respective area. A scientist using sophisticated laboratory equipment to analyze a sample of a therapeutic candidate. The analyst believes the trial's success strengthens Insmed's growth outlook and opens the door for further upside to current earnings estimates. The tone of the note reflects the analyst's strong confidence in TPIP's potential and its impact on Insmed's long-term value. Insmed Inc. (NASDAQ:INSM) is a global biopharmaceutical company that develops therapies for serious diseases. It has a commercial product, ARIKAYCE, and a pipeline that includes clinical-stage programs, brensocatib, TPIP, and INS1201, as well as pre-clinical research programs. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
11-06-2025
- Business
- Business Insider
Mizuho Securities Keeps Their Buy Rating on Insmed (INSM)
In a report released yesterday, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Insmed (INSM – Research Report), with a price target of $110.00. The company's shares closed yesterday at $90.93. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Suvannavejh is an analyst with an average return of -7.4% and a 41.75% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Verastem, and Harmony Biosciences Holdings. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Insmed with a $98.36 average price target, implying an 8.17% upside from current levels. In a report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $94.00 price target. INSM market cap is currently $13.41B and has a P/E ratio of -11.88. Based on the recent corporate insider activity of 120 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INSM in relation to earlier this year. Earlier this month, Orlov Nicole Schaeffer, the Chief People Strategy Officer of INSM sold 1,642.00 shares for a total of $117,403.00.
